The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Biologic and clinical progression in hematological malignancies at ASH 2020
Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses the developments in hematological malignancies seen at ASH 2020. With the use of single-cell mutational analysis and epigenomics tools, there is an increasing understanding of the mechanisms of disease progression and evolution. As well as this, clinical advancements have been made in every major disease area, with growing use of novel agents and new drug combinations. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
